Anticoagulation in Mitral Regurgitation

Primary Mitral Regurgitation Without Atrial Fibrillation

The American Geriatrics Society and Stroke guidelines recommend no anticoagulation for patients with primary mitral regurgitation who maintain normal sinus rhythm, even when severe 1, 2
For patients with sinus rhythm and severe mitral regurgitation, no anticoagulation is indicated unless other risk factors are present, as stated by the American Geriatrics Society 1
Prospective trials are lacking to determine whether antithrombotic therapy reduces stroke risk in mitral regurgitation patients without atrial fibrillation, according to Stroke guidelines 2

The European Heart Journal guidelines recommend anticoagulation when atrial fibrillation develops, following standard atrial fibrillation anticoagulation guidelines rather than valvular-specific protocols 3, 4
The target INR for warfarin therapy in patients with mitral regurgitation and atrial fibrillation is 2.0-3.0, as recommended by the European Heart Journal 3, 4

For patients with mechanical mitral valve replacement, the American Geriatrics Society recommends a target INR of 3.0 (range 2.5-3.5) 1
Aspirin 80-100 mg/day should be added to warfarin therapy for patients with mechanical mitral valve replacement, as stated by the American Geriatrics Society 1

The American Geriatrics Society and Stroke guidelines recommend warfarin for the first 3 months post-implantation (INR target 2.5, range 2.0-3.0) after bioprosthetic mitral valve replacement 1, 2
Aspirin 80 mg/day should be continued indefinitely after the initial 3-month period if atrial fibrillation is present, according to the American Geriatrics Society 1

The American Geriatrics Society and European Heart Journal guidelines state that mitral stenosis has entirely different anticoagulation recommendations than mitral regurgitation 1, 5
Anticoagulation is indicated with a history of systemic embolism or atrial fibrillation (Class I) in patients with mitral stenosis, as recommended by Stroke and European Heart Journal guidelines 2, 3

The Circulation guidelines recommend bridging with unfractionated heparin for high thrombotic risk patients (mechanical mitral valve, recent thrombosis, or ≥3 risk factors) undergoing noncardiac surgery 6
Risk factors for thrombotic risk include atrial fibrillation, previous embolus, hypercoagulable condition, mechanical prosthesis, and LVEF <30%, as stated by the Circulation guidelines 6

The American Geriatrics Society and Stroke guidelines recommend not anticoagulating isolated mitral regurgitation in sinus rhythm based on severity alone, as this differs fundamentally from mitral stenosis 1, 2
The European Heart Journal guidelines state that once atrial fibrillation develops, anticoagulation becomes indicated regardless of valve pathology 3, 4

The European Heart Journal guidelines state that no specific anticoagulation recommendations exist for secondary mitral regurgitation beyond standard heart failure and atrial fibrillation guidelines 7
The decision for anticoagulation in secondary mitral regurgitation is driven by the presence of atrial fibrillation, left ventricular thrombus, and standard heart failure risk stratification, as recommended by the European Heart Journal and Stroke guidelines 2, 3, 5, 7

The European Society of Cardiology recommends anticoagulation with a target INR of 2.0-3.0 using warfarin or vitamin K antagonists when atrial fibrillation develops in patients with severe mitral regurgitation 8, 9
Direct oral anticoagulants (DOACs) can be used in mitral regurgitation with atrial fibrillation, as they are not contraindicated, according to the European Heart Journal 10, 11

The European Society of Cardiology indicates anticoagulation (INR 2.0-3.0) in severe mitral regurgitation patients with a history of systemic embolism 10

Following mitral valve repair, anticoagulation is required for the first 3 months only (INR 2.0-3.0), then discontinued if sinus rhythm is maintained, as recommended by the European Society of Cardiology 8, 9
For mechanical mitral valve replacement, the American Heart Association recommends warfarin with target INR 2.5-3.5 plus aspirin 75-100 mg daily indefinitely 12
For bioprosthetic mitral valve replacement, the American Heart Association recommends warfarin for first 3 months (INR 2.0-3.0), then aspirin alone if no atrial fibrillation 12

Prospective trials have not demonstrated benefit of antithrombotic therapy for stroke prevention in mitral regurgitation patients without atrial fibrillation, according to the American Heart Association 12

The European Society of Cardiology advises against using NOACs in patients with moderate-to-severe mitral stenosis (if coexistent), as they are contraindicated 10, 11
The European Society of Cardiology recommends not delaying anticoagulation once atrial fibrillation develops, as maintenance of sinus rhythm after cardioversion is unlikely unless the mitral regurgitation is surgically corrected 8, 9